Ozempic mania fuels deal optimism across drug industry
As interest rates are stabilizing, more deals are made possible. “I haven’t felt this excited about biopharma M&A in over ten years,” says Michael Beauvais, lawyer and advisor on health deals.
By Naomi Kresge, Michelle F. Davis and Robert Langreth, Bloomberg
The world’s biggest drugmakers are racing to buy up biotech companies to fill looming holes in their pipelines and pounce on new discoveries, bringing a hopeful buzz back to JPMorgan Chase & Co.’s big health-care conference in San Francisco.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Roche still deal hunting within obesity indication
For subscribers
